Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tagamet 100

This article was originally published in The Tan Sheet

Executive Summary

SmithKline Beecham receives license in the U.K. to market its 100 mg nonprescription formulation of the H[2] antagonist cimetidine for the relief of heartburn and dyspepsia, the company announced March 9. The OTC product is expected to be available "in the near future," SmithKline Beecham said. Cimetidine was one of 11 Rx-to-OTC switches approved by the U.K. Medicines Control Agency in a Jan. 21 order ("The Tan Sheet" Feb. 21, p. 6). J&J- Merck's H[2] antagonist famotidine, launched as Pepcid AC by the joint venture's new U.K. subsidiary, Centra Health Care, was also switched on Jan. 21; however, only cimetidine is indicated for the prevention of nocturnal heartburn as well as daytime treatment. Labeling directs consumers to take either two 100 mg tablets at the onset of symptoms, or one 100 mg tablet prophylactically at bedtime

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS082567

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel